natgillin/translations-raw huggingface dataset:
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myclausen is not required.
Reakcija odbacivanja presađenog bubrega ne dovodi do promjena u farmakokinetici MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Myclausena.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Mycophenolate mofetil Teva is not required.
Reakcija odbacivanja presađenog bubrega ne dovodi do promjena u farmakokinetici MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Mikofenolat mofetil Teva.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myfenax is not required.
Reakcija odbacivanja presađenog bubrega ne dovodi do promjena u farmakokinetici MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Myfenaxa.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dose reduction or interruption of Mycophenolate mofetil Teva is not required.
Reakcija odbacivanja presađenog bubrega ne dovodi do promjena u farmakokinetici MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Mikofenolat mofetila Teva.
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dose reduction or interruption of Myfenax is not required.
Reakcija odbacivanja presađenog bubrega ne dovodi do promjena u farmakokinetici MPA pa nije potrebno smanjiti dozu ni prekinuti primjenu Myfenaxa.
renal tubular
bubrežna tubularna acidoza
renal tubular acidosis
renalna tubularna acidoza
Renal tubular disorder (acquired Fanconi syndrome), glycosuria
poremećaj bubrežnih tubula (stečeni Fanconijev sindrom), glikozurija
renal tubular necrosis, proteinuria, nephritis
bubrežna tubularna nekroza, proteinurija, nefritis
Renal/hepatic impairment
Oštećenje bubrežne/jetrene funkcije
Renal/hepatic impairment
Oštećenje funkcije bubrega i jetre
Renal/hepatic impairment
Oštećenje funkcije bubrega/jetre
Renally eliminated medicinal products
Lijekovi koji se eliminiraju putem bubrega
Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Atripla with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.
Lijekovi koji se eliminiraju bubrezima: Kako se emtricitabin i tenofovir primarno eliminiraju putem bubrega, istovremena primjena Atriple i lijekova koji smanjuju funkciju bubrega ili se natječu za aktivnu tubularnu sekreciju (npr. cidofovir) može povećati serumske koncentracije emtricitabina, tenofovira i/ili istovremeno primijenjenih lijekova.
Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Truvada with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.
Lijekovi koji se eliminiraju bubrezima: Kako se emtricitabin i tenofovir primarno eliminiraju putem bubrega, istovremena primjena Truvade i lijekova koji smanjuju funkciju bubrega ili se natječu za aktivnu tubularnu sekreciju (npr. cidofovir) može povećati serumske koncentracije emtricitabina, tenofovira i/ili istovremeno primijenjenih lijekova.
Renally impaired patients
Bolesnici s oštećenjem funkcije bubrega
Renally or hepatically impaired patients: No dose adjustment is necessary.
Bolesnici s oštećenjem bubrega ili jetre: nije potrebno prilagođavati dozu.
Renally-impaired patients
Bolesnici s oštećenjem bubrega
Renin inhibitors suppress the enzymatic activity of renin, and thereby block the formation of Angiotensin II, the major effector molecule of the renin-angiotensin-aldosterone system (RAAS).
Inhibitori renina suzbijaju enzimatsku aktivnost renina i tako blokiraju stvaranje angiotenzina II, glavne efektorske molekule renin- angiotenzin-aldosteron sustava (RAAS).
Rensselaer, NY 12144 United States
Rensselaer, NY 12144 Sjedinjene Američke Države
Rensselaer, NY 12144 USA
Rensselaer, NY 12144 SAD
Renvela 1.6 g powder for oral suspension
Renvela 1,6 g prašak za oralnu suspenziju
Renvela 2.4 g powder for oral suspension
Renvela 2,4 g prašak za oralnu suspenziju
Renvela 800 mg film-coated tablets
Renvela 800 mg filmom obložene tablete
Renvela contains sevelamer carbonate as the active ingredient.
Renvela sadrži djelatnu tvar sevelamerkarbonat.
Renvela film-coated tablets are white tablets with RENVELA 800 imprinted on one side.
Renvela filmom obložene tablete su bijele tablete, s otisnutom oznakom RENVELA 800 na jednoj strani.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.
Renvela je indicirana i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu > 1,78 mmol/l.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease patients not on dialysis with serum phosphorus > 1.78 mmol/l.
Renvela je indicirana i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu > 1,78 mmol/l.
Renvela is not absorbed and may affect the bioavailability of other medicinal products.
Renvela se ne apsorbira i može utjecati na bioraspoloživost drugih lijekova.
Renvela is not absorbed compound and may affect the bioavailability of other medicinal products.
Renvela se ne apsorbira i može utjecati na bioraspoloživost drugih lijekova.
Renvela is not indicated for the control of hyperparathyroidism.
Renvela nije indicirana za kontrolu hiperparatireoze.
Renvela is used to control hyperphosphataemia (high blood phosphate levels) in: adult patients on dialysis (a blood clearance technique).
Renvela se koristi za kontorolu hiperfosfatemije (visoka razina fosfata u krvi) u: odraslih bolesnika na dijalizi (tehnika pročišćavanja krvi).
Renvela powder for oral suspension must be taken three times per day with meals.
Renvela prašak za oralnu suspenziju mora se uzimati triput na dan uz obrok.
Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Renvela se treba koristiti zajedno s ostalim metodama liječenja poput nadomjestaka kalcija i primjene vitamina D, kako bi se spriječio razvoj bolesti kostiju.
Renvela should not be taken at the same time as ciprofloxacin (an antibiotic).
Renvela se ne bi smjela uzimati istodobno s ciprofloksacinom (antibiotik).
Renvela should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.
Renvela se smije davati trudnicama samo ako je to prijeko potrebno i nakon pažljive analize rizika i koristi kako za majku tako i za fetus.
Renvela treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
Treba ponovno procijeniti nastavak liječenja lijekom Renvela u bolesnika koji razviju tešku konstipaciju ili im se jave drugi teški gastrointestinalni simptomi.
Reoccurrence of Thrombocytopenia
Ponavljanje trombocitopenije
Repaglinide
repaglinid
Repaglinide (CYP2C8 and OATP1B1
Repaglinid (supstrat za CYP2C8 i OATP1B1)
repaglinide (used to treat diabetes),
repaglinid (koristi se za liječenje šećerne bolesti),
Repaglinide Accord 0.5 mg
Repaglinid Accord 0,5 mg
Repaglinide Accord 0.5 mg tablets
Repaglinid Accord 0,5 mg tablete
Repaglinide Accord 0.5 mg tablets Repaglinide
Repaglinid Accord 0,5 mg tablete repaglinid
Repaglinide Accord 0.5 mg tablets Repaglinide Accord 1 mg tablets Repaglinide Accord 2 mg tablets Repaglinide
Repaglinid Accord 0,5 mg tablete Repaglinid Accord 1 mg tablete Repaglinid Accord 2 mg tablete repaglinid
Repaglinide Accord 0.5 mg: Each tablet contains 0.5 mg repaglinide Repaglinide Accord 1 mg: Each tablet contains 1 mg repaglinide Repaglinide Accord 2 mg: Each tablet contains 2 mg repaglinide
Repaglinid Accord 0,5 mg: Svaka tableta sadrži 0,5 mg repaglinida Repaglinid Accord 1 mg: Svaka tableta sadrži 1 mg repaglinida Repaglinid Accord 2 mg: Svaka tableta sadrži 2 mg repaglinida
Repaglinide Accord 1 mg
Repaglinid Accord 1 mg
Repaglinide Accord 1 mg tablets
Repaglinid Accord 1 mg tablete
Repaglinide Accord 1 mg tablets Repaglinide
Repaglinid Accord 1 mg tablete repaglinid
Repaglinide Accord 2 mg
Repaglinid Accord 2 mg
Repaglinide Accord 2 mg tablets
Repaglinid Accord 2 mg tablete
Repaglinide Accord 2 mg tablets Repaglinide
Repaglinid Accord 2 mg tablete repaglinid
Repaglinide Accord has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.
Repaglinid Accord nema izravnog učinka na sposobnost upravljanja vozilima i rada na strojevima, ali može uzrokovati hipoglikemiju.
Repaglinide Accord should not be taken if you have a severe liver disease (see Do not take Repaglinide Accord).
Repaglinid Accord ne smijete uzimati ako imate tešku bolest jetre (vidjeti Nemojte uzimati Repaglinid Accord ).
Repaglinide exposure is increased in patients with hepatic insufficiency and in the elderly type 2 diabetic patients.
Izloženost repaglinidu povećana je u bolesnika s insuficijencijom jetre te u starijih bolesnika sa šećernom bolešću tipa 2.
Repaglinide has been given with weekly escalating doses from 4 – 20 mg four times daily in a 6 week period.
Repaglinid je primjenjivan u tjedno povećavanim dozama od 4-20 mg četiri puta dnevno u razdoblju od 6 tjedana.
Repaglinide is . not affected by renal disorders (see section 5.2).
Na repaglinid ne utječu poremećaji bubrega (vidjeti dio 5.2).
Repaglinide is a short-acting oral secretagogue.
Repaglinid je kratkodjelujući oralni lijek koji potiče izlučivanje inzulina.
Repaglinide is a short-acting oral secretagogue.
Repaglinid je kratkodjelujući oralni lijek koji potiče lučenje inzulina.
Repaglinide Krka 0.5 mg tablets Repaglinide
Repaglinid Krka 0,5 mg tablete repaglinid
Repaglinide Krka 1 mg tablets Repaglinide
Repaglinid Krka 1 mg tablete repaglinid
Repaglinide Krka 2 mg tablets Repaglinide
Repaglinid Krka 2 mg tablete repaglinid
Repaglinide Krka should not be taken if you have a severe liver disease (see Do
Repaglinid Krka ne smijete uzimati ako imate tešku bolest jetre (vidjeti Nemojte uzimati Repaglinid Krka).
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 98%).
Farmakokinetika repaglinida karakterizirana je malim volumenom distribucije, 30 l (što je sukladno s distribucijom u unutarstaničnoj tekućini) i u velikom se postotku veže za proteine plazme u ljudi (više od 98%).
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid), and is highly bound to plasma proteins in humans (greater than 98%).
Farmakokinetika repaglinida karakterizirana je malim volumenom distribucije, 30 l (što je sukladno s distribucijom u unutarstaničnoj tekućini) i u velikom se postotku veže za proteine plazme u ljudi (više od 98%), te se brzo eliminira iz krvi.
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid), and is highly bound to plasma proteins in humans (greater than 98%).
Farmakokinetika repaglinida karakterizirana je malim volumenom distribucije, 30 l (što je sukladno s distribucijom u unutarstaničnoj tekućini) i u velikom se postotku veže za proteine plazme u ljudi (više od 98%).
Repaglinide Teva 0.5 mg tablets
Repaglinid Teva 0,5 mg tablete
Repaglinide Teva 0.5 mg tablets Repaglinide
Repaglinid Teva 0,5 mg tablete repaglinid
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets
Repaglinid Teva 0,5 mg tablete Repaglinid Teva 1 mg tablete Repaglinid Teva 2 mg tablete
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets Repaglinide
Repaglinid Teva 0,5 mg tablete Repaglinid Teva 1 mg tablete Repaglinid Teva 2 mg tablete repaglinid
Repaglinide Teva 1 mg tablets
Repaglinid Teva 1 mg tablete
Repaglinide Teva 1 mg tablets Repaglinide
Repaglinid Teva 1 mg tablete repaglinid
Repaglinide Teva 2 mg tablets
Repaglinid Teva 2 mg tablete
Repaglinide Teva 2 mg tablets Repaglinide
Repaglinid Teva 2 mg tablete repaglinid
repaglinide – a medicine used to treat diabetes
repaglinid – lijek koji se primjenjuje u liječenju šećerne bolesti
repaglinide, glibenclamide (used to treat high blood sugar)
repaglinid, glibenklamid (koriste se za liječenje visoke razine šećera u krvi)
repaglinide, medicine to treat diabetes paclitaxel, medicine to treat cancer.
repaglinid, lijek za liječenje dijabetesa, paklitaksel, lijek za liječenje raka.
repaglinide, medicine to treat diabetes, paclitaxel, medicine to treat cancer.
repaglinid, lijek za liječenje dijabetesa, paklitaksel, lijek za liječenje raka.
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
repaglinid, pioglitazon, nateglinid ili roziglitazon za liječenje šećerne bolesti
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
repaglinid, pioglitazon, nateglinid ili roziglitazon za šećernu bolest
Repaglinide: AUCinf: ↓ 8%
Repaglinid: AUCinf: ↓ 8
Repatha 140 mg solution for injection evolocumab
Repatha 140 mg otopina za injekciju evolokumab
Repatha 140 mg solution for injection in pre-filled pen
Repatha 140 mg otopina za injekciju u napunjenoj brizgalici
Repatha 140 mg solution for injection in pre-filled pen evolocumab
Repatha 140 mg otopina za injekciju u napunjenoj brizgalici evolokumab
Repatha 140 mg solution for injection in pre-filled syringe
Repatha 140 mg otopina za injekciju u napunjenoj štrcaljki.
Repatha 140 mg solution for injection in pre-filled syringe evolocumab
Repatha 140 mg otopina za injekciju u napunjenoj štrcaljki evolokumab
Repatha 140 pen
Repatha 140 brizgalica
Repatha 140 syringe
Repatha 140 štrcaljka
Repatha evolocumab
Repatha evolokumab
Repatha has no known influence on the ability to drive and use machines.
Utjecaj lijeka Repatha na sposobnost upravljanja vozilima i rada sa strojevima nije poznat.
Repatha has not been studied in patients with severe renal impairment (see section 4.4).
Repatha nije ispitivana u bolesnika s teškim oštećenjem bubrega (vidjeti dio 4.4).
Repatha is a medicine that lowers levels of ’bad’ cholesterol, a type of fat, in the blood.
Repatha je lijek koji snižava razine „lošeg“ kolesterola, oblika masti, u krvi.
Repatha is a medicine used to treat:
Repatha je lijek koji se primjenjuje u liječenju:
Repatha is also used to treat mixed dyslipidaemia (abnormal levels of fats in blood, including high levels of LDL-cholesterol).
Repatha se također primjenjuje u terapiji miješane dislipidemije (abnormalnih koncentracija masti u krvi, uključujući visoke razine LDL kolesterola).
Repatha is available as a solution for injection in a pre-filled syringe or pre-filled pen (140 mg).
Lijek Repatha dostupan je kao otopina za injekciju u napunjenoj štrcaljki ili napunjenoj brizgalici (140 mg).
Repatha is to be used together with a low-fat diet, in the following cases:
Lijek Repatha treba primjenjivati s prehranom siromašnom mastima u sljedećim slučajevima:
Repatha is used in addition to your cholesterol lowering diet if you are: an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia).
Repatha se koristi kao dodatak dijeti za snižavanje razine kolesterola ako: ste odrasla osoba s visokom razinom kolesterola u krvi (primarna hiperkolesterolemija [heterozigotna obiteljska i stečena] ili miješana dislipidemija).
Repatha reduced LDL-C, non-HDL-C, Apo B, TC, Lp(a), VLDL-C, TG, TC/HDL-C, and ApoB/ApoA1and increased HDL-C in patients with mixed dyslipidaemia.
Repatha je smanjila vrijednosti LDL-C-a, non-HDL-C-a, ApoB-a, TC-a, Lp(a)-a, VLDL-C-a, TG-a, TC/HDL-C-a te ApoB/ApoA1-a, a povećala vrijednosti HDL-C-a u bolesnika s miješanom dislipidemijom.
Repatha should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.
Repatha se ne smije primjenjivati tijekom trudnoće, osim ako kliničko stanje žene ne zahtijeva liječenje s evolokumabom.
Repatha significantly reduced LDL-C from baseline at week 12 compared with control (nominal p < 0.001).
Repatha je značajno smanjila LDL-C u odnosu na početne vrijednosti u 12. tjednu u usporedbi s kontrolom (nominalna p vrijednost < 0,001).
Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001).
Repatha je značajno smanjila početne vrijednosti LDL- C-a do srednje vrijednosti u 10. i 12. tjednu u usporedbi i s placebom i s ezetimibom (p < 0,001).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 VLDL-C, TG and Lp(a) and increased HDL-C and ApoA1 from baseline to mean of weeks 10 and 12 compared to placebo (p < 0.05) (see table 2).
Repatha je značajno smanjila početne vrijednosti TC-a, ApoB-a, non-HDL-C-a, TC/HDL-C-a, ApoB/ApoA1-a, VLDL-C-a, TG-a i Lp(a)-a te povećala početne vrijednosti HDL-C-a i ApoA1-a do srednje vrijednosti u 10. i 12. tjednu, u odnosu na placebo (p < 0,05) (vidjeti Tablicu 2).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) , and increased HDL-C and ApoA1 from baseline to week 52 in OSLER and to week 24 in OSLER-2 compared with control (nominal p < 0.001).
Repatha je značajno smanjila TC, ApoB, non-HDL-C, TC/HDL- C, ApoB/ApoA1, VLDL-C, TG i Lp(a) te povećala HDL-C i ApoA1 u odnosu na početne vrijednosti do 52. tjedna u OSLER i 24. tjedna u OSLER-2 ispitivanju, u usporedbi s kontrolom (nominalna p vrijednost < 0,001).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 at week 52 compared with placebo (p < 0.001) (table 4).
Repatha je značajno smanjila vrijednosti TC-a, ApoB-a, non-HDL-C-a, TC/HDL-C-a, ApoB/ApoA1-a, VLDL-C-a, TG-a i Lp(a)-a te povećala vrijednosti HDL-C-a i ApoA1-a u 52. tjednu u usporedbi s placebom (p < 0,001) (tablica 4).
Repatha single use pre-filled syringe
Repatha napunjena štrcaljka za jednokratnu primjenu
Repatha single use SureClick pre-filled pen
Repatha SureClick napunjena brizgalica za jednokratnu primjenu
Repatha was compared to placebo for the rosuvastatin and simvastatin groups and compared with placebo and ezetimibe for the atorvastatin group.
Kombinacija lijeka Repatha s rosuvastatinom odnosno simvastatinom uspoređivana je s placebom, dok je kombinacija primjene s atorvastatinom uspoređivana s placebom i ezetimibom.
Repatha was superior to ezetimibe in reducing LDL-C, TC, ApoB, non-HDL-C, Lp(a), TC/HDL-C, and ApoB/ApoA1.
Repatha se pokazala superiornijom od ezetimiba u snižavanju vrijednosti LDL-C-a, TC-a, ApoB-a, non- HDL-C-a, Lp(a)-a, TC/HDL-C-a i ApoB/ApoA1-a.
Repeat administration every 12 months to maintain efficacy.
Aplikaciju ponoviti na svakih 12 mjeseci radi održanja djelotvornosti.
Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in an approximately a 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state is achieved by approximately Day 15.
Ponavljanje dnevne doze kabozantiniba od 140 mg tijekom 19 dana rezultiralo je otprilike četverostruko do peterostruko većom srednjom vrijednosti akumulacije kabozantiniba (na osnovu AUC) u usporedbi s primjenom jedne doze; stanje dinamičke ravnoteže je postignuto otprilike 15.- og dana.
Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician’s opinion may benefit from retreatment without being exposed to significant risk (see section 5.1).
Potrebno je razmotriti ponavljanje doze kada bolesnik osjeti reakciju na liječenje nakon koje slijedi smanjenje oštrine vida i ako mu, prema mišljenju liječnika, ponovljeni tretman može koristiti, a da nije izložen značajnom riziku (vidjeti dio 5.1).
Repeat Evaluation (N=23)
Ponovljena procjena (N=23)
Repeat every 24 – 72 hours for the first week, and then maintenance dose 1 – 2 times per week until bleeding stops and healing is achieved.
Ponavljati svakih 24 – 72 sata tijekom prvih tjedan dana, a zatim primjenjivati dozu održavanja 1 – 2 puta na tjedan dok se ne zaustavi krvarenje i postigne zacjeljenje.
Repeat every 24 – 72 hours for the first week, and then maintenance dose weekly until bleeding stops and healing is achieved.
Ponavljati svakih 24 – 72 sata tijekom prvih tjedan dana, a zatim primjenjivati dozu održavanja jedanput na tjedan dok se ne zaustavi krvarenje i postigne zacjeljenje.
Repeat infusion every
Ponovite infuziju svakih
Repeat infusion every
zahvata)
Repeat infusion every 12 - 24 hours for 3 - 4 days or more until pain and acute disability are resolved.
Ponoviti infuziju svakih 12 – 24 sata tijekom 3 – 4 dana ili dulje do prestanka boli i akutne onesposobljenosti.
Repeat infusion every 12 - 24 hours for 3 - 4 days or more until pain and acute disability are resolved.
Ponoviti infuziju svakih 12 – 24 sata tijekom 3 – 4 dana ili dulje do prestanka boli i akutne onesposobljnosti.
Repeat infusion every 12 - 24 hours for 3 - 4 days or more until pain and disability are resolved.
Ponoviti infuziju svakih 12 – 24 sata tijekom 3 – 4 dana ili dulje do prestanka boli i tegoba.
Repeat infusion every 12 to 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Ponovite infuziju svakih 12 - 24 sata tijekom najmanje 1 dana sve dok se ne riješi bolna epizoda krvarenja ili ne postigne zacjeljivanje.
Repeat infusion every 12 to 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Ponovite infuziju svakih 12 - 24 sata tijekom najmanje jednog dana sve dok se ne riješi bolna epizoda krvarenja ili ne postigne zacjeljivanje.
Repeat infusion every 12 to 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Ponovite infuziju svakih 12 – 24 sata tijekom najmanje jednog dana sve dok se ne riješi bolna epizoda krvarenja ili ne postigne zacjeljivanje.
Repeat infusion every 24 hours for
Ponoviti infuziju svaka 24 sata tijekom
Repeat infusion every 24 hours for 3-4 days or
Ponavljati infuziju svaka 24 sata tijekom 3
Repeat infusion every 8 - 24 hours
Ponoviti infuziju svakih 8 – 24 sata do
Repeat infusion every 8 - 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dL).
Ponoviti infuziju svakih 8 – 24 sata do odgovarajućeg zacjeljivanja rane, zatim terapija još najmanje 7 dana kako bi se aktivnost faktora VIII održala na razini od 30% do 60% (IU/dl).
Repeat infusion every 8 to 24 hours
Ponoviti infuziju svakih 8 do 24 sata
Repeat infusion every 8 to 24 hours until threat
Ponavljati infuziju svakih 8 do 24 sata dok
Repeat infusion every 8 to 24 hours until threat is resolved.
sata sve do otklanjanja životne opasnosti.
Repeat infusion every 8-24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor VIII activity of 30% - 60% (IU/dl)
Ponovite infuziju svakih 8 - 24 sata sve dok se ne postigne odgovarajuće cijeljenje rane, a potom nastavite s liječenjem tijekom najmanje 7 dodatnih dana kako biste održali aktivnost faktora VIII od 30% do 60% (IU/dl)
Repeat infusion every 8-24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a factor VIII activity of 30% - 60% (IU/dl)
Ponovite infuziju svakih 8 do 24 sata sve dok se ne postigne odgovarajuće cijeljenje rane, a potom nastavite s liječenjem drugih 7 dana kako bi se održala aktivnost faktora VIII od 30% do 60%. (IU/dl).